Select Bibliography

Filter by any of these (after searching):

Dy, G

There are 20 items

A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study.

Adjei, A. A. , Mandrekar, S. J. , Dy, G. K. , Molina, J. R. ... - - J. Clin. Oncol. - 2008

Abstract - Primary - Primary - Respiratory - NCCTG-N0426

Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426

Adjei, A. A. , Mandrekar, S. J. , Dy, G. K. , Molina, J. R. ... - - J. Clin. Oncol. - 2010

Manuscript - Primary - Primary - Respiratory - N0426

Correlation between polymorphisms in the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer (NSCLC): An NCCTG N0026 based study. Abstract 198.

Adjei, A. , Salavaggione, O. , Mandrekar, S. , Dy, G. ... - NCI TSM - - 2009

Abstract - Secondary-not-in-original - Primary - Respiratory - NCCTG-N0026

Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study.

Adjei, Araba A , Salavaggione, Oreste E , Mandrekar, Sumithra J ... - - J Thorac Oncol - 2010

Manuscript - Secondary-not-in-original - Primary - Respiratory - N0026

Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial

Basch, Ethan , Stover, Angela M. , Schrag, Deborah , Chung, Arlene ... - - JCO Clin Cancer Inform - 2020

Manuscript - Primary - Primary - Health Outcome - AFT-39

A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC).

Dy, G. K. , Mandrekar, S. J. , Nelson, G. D. , Ross, H. J. ... - - J. Clin. Oncol. - 2010

Abstract - Primary - Primary - Respiratory - NCCTG-N0528

N0821: A phase II first-line study of a combination of pemetrexed (P), carboplatin (C), and bevacizumab (B) in elderly patients with good performance status (PS < 2)

Dy, G. K. , Molina, J. , Qi, Y. , Ansari, R. H. , Thomas, S. ... - - J. Clin. Oncol. - 2012

Abstract - Primary - Primary - Respiratory - NCCTG-N0821

A Front-Line “Window of Opportunity” Phase II Study of Sorafenib in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)– A North Central Cancer Treatment Group Study N03261

Dy, Grace K. , Hillman, Shauna L. , Rowland, Kendrith M. ... - - Cancer - 2010

Manuscript - Primary - Primary - Respiratory - N0326

Long-Term Survivors of Metastatic Colorectal Cancer Treated with Systemic Chemotherapy Alone: A North Central Cancer Treatment Group Review of 3811 Patients, N0144

Dy, Grace K. , Hobday, Timothy J. , Nelson, Garth ... - - Clin Colorectal Cancer - 2009

Manuscript - Primary - Primary - GI - N0144

A Randomized Phase II Study of Gemcitabine and Carboplatin With or Without Cediranib as First-Line Therapy in Advanced Non-Small Cell Lung Cancer: North Central Cancer Treatment Group Study N0528

Dy, Grace K. , Mandrekar, Sumithra J. , Nelson, Garth D. ... - - J Thorac Oncol - 2013

Manuscript - Primary - Primary - Respiratory - NCCTG-N0528

NCCTG N0821 (Alliance): A phase II first-line study of pemetrexed, carboplatin and bevacizumab in elderly patients with advanced nonsquamous non-small cell lung cancer with good performance status

Dy, Grace K. , Molina, Julian R. , Qi, Yingwei , Ansari, Rafat ... - - J Thorac Oncol - 2014

Manuscript - Primary - Primary - Respiratory - NCCTG-N0821

Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.

Dy, Grace K , Krook, James E , Green, Erin M , Sargent, Daniel J ... - - J. Clin. Oncol. - 2007

Manuscript - Secondary - Primary - GI - N9741

Impact of disease progression (DP) date determination method on post progression survival (PPS) and DP metrics in advanced lung cancer

Mandrekar, Sumithra J. , Foster, Nathan R. , Qi, Yingwei ... - ASCO - J. Clin. Oncol. - 2012

Abstract - No-Endpoint - Comprehensive - Respiratory - N0424

A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second line therapy in advanced non-small cell lung cancer (NSCLC) of non-squamous histology: NCCTG N0626 study

Molina, J. R. , Dy, G. K. , Foster, N. R. , Ziegler, Allen ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Primary - Primary - Respiratory - N0626

A randomized double-blinded phase II study of the Seneca Valley Virus (NTX-010) vs placebo for patients with extensive stage SCLC (ES-SCLC) who were stable or responding after at least 4 cycles of platinum-based chemotherapy: NCCTG N0923 (Alliance) Study

Molina, J. R. , Mandrekar, S. J. , Dy, G. , Aubry, M. C. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary - Primary - Respiratory - N0923

Incidence of bleeding and thrombosis among elderly patients undergoing systemic chemotherapy in advanced non-small cell lung cancer: An analysis of North Central Cancer Treatment Group trials

Qi, Y. , Dy, G. K. , Nelson, G. D. , Schild, S. E. , Mandrekar, S. J. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Secondary - Primary - Respiratory - N0424

Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study.

Reungwetwattana, Thanyanan , Molina, Julian R ... - - J Thorac Oncol - 2012

Manuscript - Primary - Primary - Respiratory - N0323

A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 Study.

Schenk, Erin L , Mandrekar, Sumithra J , Dy, Grace K ... - - J Thorac Oncol - 2020

Manuscript - Primary - Primary - Respiratory - N0923

N0321: A phase II study of bortezomib, paclitaxel, carboplatin, and radiotherapy for locally advanced non-small cell lung cancer

Schild, S. E. , Molina, J. R. , Dy, G. K. , Rowland, K. M., Jr ... - - J. Clin. Oncol. - 2012

Abstract - Primary - Primary - Respiratory - NCCTG-N0321

N0321: A Phase I Study of bortezomib, Paclitaxel, Carboplatin (CBDCA) & Radiotherapy (RT) for Locally-Advanced Non-Small Cell Lung Cancer (NSCLC)

Schild, S. , Molina, J. , Dy, G. , Rowland, K., Jr , Sarkaria, J. ... - - J. Clin. Oncol. - 2010

Abstract - Primary - Preliminary - Respiratory - NCCTG-N0321